Detection of new protein domains using co-occurrence: application to Plasmodium falciparum by Terrapon, Nicolas et al.
Detection of new protein domains using co-occurrence:
application to Plasmodium falciparum
Nicolas Terrapon, Olivier Gascuel, Eric Mare´chal, Laurent Brehelin
To cite this version:
Nicolas Terrapon, Olivier Gascuel, Eric Mare´chal, Laurent Brehelin. Detection of new protein
domains using co-occurrence: application to Plasmodium falciparum. Bioinformatics, Oxford




Submitted on 17 May 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
BIOINFORMATICS Vol. 00 no. 00 2008Pages 1–7
Detection of new protein domains using co-occurrence:
application to Plasmodium falciparum
Nicolas Terrapon 1,2, Olivier Gascuel 1, ´Eric Mare´chal 2 and
Laurent Bre´he´lin 1,∗
1Me´thodes et algorithmes pour la Bioinformatique, LIRMM, Univ. Montpellier 2, CNRS, 161 rue Ada
34392 Montpellier Cedex 5 France
2CEA Grenoble iRTSV/LPCV, 17 rue des Martyrs, 38054 Grenoble cedex 9 France
Received on XXXXX; revised on XXXXX; accepted on XXXXX
Associate Editor: XXXXXXX
ABSTRACT
Motivation: Hidden Markov Models (HMMs) have proved to be a
powerful tool for protein domain identification in newly sequenced
organisms. However, numerous domains may be missed in highly
divergent proteins. This is the case for Plasmodium falciparum
proteins, the main causal agent of human malaria.
Results: We propose a method to improve the sensitivity of HMM
domain detection by exploiting the tendency of the domains to
appear preferentially with a few other favorite domains in a protein.
When sequence information alone is not sufficient to warrant the
presence of a particular domain, our method enables its detection
on the basis of the presence of other Pfam or InterPro domains.
Moreover, a shuffling procedure allows us to estimate the false
discovery rate associated with the results. Applied to P. falcipa-
rum, our method identifies 585 new Pfam domains (versus the 3 683
already known domains in the Pfam database) with an estimated error
rate below 20%. These new domains provide 387 new Gene Ontology
annotations to the P. falciparum proteome. Analogous and congruent
results are obtained when applying the method to related Plasmodium
species (P. vivax and P. yoelii).
Availability: Supplementary Material and a database of the new




Among relevant annotations that can be attached to a protein,
domains occupy a key position. Protein domains are sequential and
structural motifs that are found independently in different proteins,
in different combinations and, as such, seem to be functional
sub-units of proteins above the raw amino-acid sequence level
(Richardson, 1981). Several approaches have been developed to
define and identify domains. Some are based on observed distinct
structural classes of proteins (Murzin et al., 1995). Others are
inferred by clustering conserved subsequences (Mulder et al., 2007;
Finn et al., 2008). One of the most widely used domain schemata
is the Pfam database (Finn et al., 2008). In this database, each
∗to whom correspondence should be addressed
domain family is defined with a set of distinct representative protein
sequences, manually selected and aligned, and used to learn a
Hidden Markov Model (HMM) (Durbin et al., 1998) of the domain.
The current release of the Pfam database (version 23.0 of July 2008)
offers a large collection of 10 340 HMMs/domains, which account
for over 73% of all proteins in the Uniprot database (UniProt
Consortium, 2009). Some Pfam HMMs have been annotated by
the InterPro consortium (Mulder et al., 2007) in the Gene Ontology
(GO) (Gene Ontology Consortium, 2000). According to the InterPro
annotation policy, a domain is annotated with a given GO term if all
proteins where this domain is known also share this GO term. This
stringent rule allows, when a new domain is detected in a protein,
transfer of its annotations to this protein.
When analyzing a new protein sequence, each Pfam HMM is
used to compute a score that measures the similarity between
the sequence and the domain. If the score is above a given
threshold provided by Pfam (score thresholds differ depending on
the HMMs), then the presence of the domain can be asserted in
the protein. However, when applied to highly divergent proteins,
this strategy may miss numerous domains. For example, with
Plasmodium falciparum, the main causal agent of human malaria,
no Pfam domains are detected in nearly 50% of its proteins,
while many domain types seem to be missing from the P. falci-
parum library—see Supp. Table 1 for a comparison of the protein
coverage and domain numbers between several eukaryotes. This
can be partly explained by the highly atypical genome of P. fal-
ciparum, which is composed of above 80% A+T, and involves
long low-complexity insertions of unknown function believed to
form non-globular domains (Pizzi and Frontali, 2001). This strongly
biases the amino-acid composition of P. falciparum proteome, in
which six amino acids account for more than 50% of the protein
composition (Bastien et al., 2005). In this article, we propose a
new method to increase the sensitivity of Pfam domain detection
in divergent proteins like those of P. falciparum. Our method
involves lowering the thresholds provided by Pfam for detecting
domains. This enables more domain detections, but at the expense
of numerous false positive predictions. The core of the method is
a filter procedure based on domain co-occurrence properties which
selects the potential domains that are most likely true.
© Oxford University Press 2008. 1
Terrapon et al
Several authors have studied domain combinations in proteins
(Apic et al., 2001). They showed that numerous domains are
frequently found together. As a result, the number of observed
domain combinations in nature is clearly less than the number of
possibilities. The domains tend to appear with a few other favorite
domains. For example, when computing the number of distinct
Pfam domain pairs observed in Uniprot proteins, only 20 000 out
of the ∼12.5 million possibilities are observed (a ratio of 1.6‰).
This property suggests functional cooperation. Indeed, two thirds of
mono-domain proteins having the same domain also have the same
functions. For multidomain proteins, 35% of proteins having one
identical domain have similar functions, while this rate increases to
80% when they share two identical domains (Gerstein and Hegyi,
2001). This is the basis of approaches used to predict protein
functional annotations. Scott et al. (2004) use Bayesian networks of
co-occuring motifs to predict sub-cellular localizations of proteins.
McLaughlin et al. (2007) characterize domain assembly (DASSEM)
units, i.e. groups of domains that cooperate to achieve a given
function. Forslund and Sonnhammer (2008) propose an approach
to predict specific GO annotations from domain groups. Geer et al.
(2002) present the CDART tool that allows users to find proteins
having a domain composition similar to that of the query protein. In
this paper, we propose to use domain co-occurrence to improve the
sensitivity of Pfam domain detection.
In the following, we first describe our approach and present a
shuffling procedure that allows estimation of its false discovery rate
(FDR). Next, the method is assessed by searching for domains
in artificial proteins obtained by simulating evolution events in
the yeast proteins. Finally, our approach is applied to P. falci-
parum. In this organism, it detects 558 additional domains with
an estimated FDR below 20%. Among these new domains, 159
domain types have never before been detected in P. falciparum
proteins. Moreover, these domains provide 387 new Gene Ontology
annotations. Analogous and congruent results are obtained when
applying this method to related Plasmodium species (P. vivax and
P. yoelii).
2 METHOD
In the following, the domain composition of a protein is the set of domains
it contains. Thus, both the sequential order of the domains, as well as
the number of times each domain occurs is ignored. This is done on the
grounds of the assumption that the presence/absence of a domain is the
prime information for deciphering the protein function (Cohen-Gihon et al.,
2007). For each protein, we distinguish two types of known domains: Pfam
domains and InterPro non-Pfam domains. Known Pfam domains are all Pfam
domains above the stringent score thresholds provided by Pfam (“gathering
cut-offs”), or whose presence has been asserted by experts and can be found
in dedicated databases of the query organism—for example, PlasmoDB for
P. falciparum (Bahl et al., 2003). The InterPro domains come from the
InterPro database (Mulder et al., 2007), a meta-database of different domain
databases: PROSITE, PRINTS, ProDom, SMART, TIGRFAMs, PIRSF,
SUPERFAMILY, Gene3D, PANTHER and Pfam (see Mulder et al. (2007)
for references). InterPro incorporates this knowledge into a single resource
by organizing entries in InterPro families pooling all representations of the
same domain. The known InterPro domains of a protein are inferred with
InterProScan software, and can be found in the dedicated databases of the
organisms.
We aim to enrich the known Pfam domains of a query organism (P. fal-
ciparum). The principle is to use domain co-occurrence properties to certify
the presence of a new potential Pfam domain in a protein, thanks to the
presence of another validating domain. To this end, all Uniprot proteins
with known domain composition were used to extract domain pairs showing
strong co-occurrence (as assessed by a statistical test). These domain pairs
are stored in a reference list of Conditionally Dependent Pairs (CDP), which
is then used as follows. Let us consider a protein of the query organism
where one or more potential Pfam domains are detected by lowering the
score thresholds of the Pfam HMMs. If one of these potential domains
forms, along with another non-overlapping domain of the protein, a pair
that belongs to the CDP list, then the presence of the potential domain
is considered as certified. Hence, to apply this method we need a set of
validating domains Vi and a set of potential domains Pi for each protein i
of the query organism. We also have to infer the CDP list {(A,B), A 6= B}
from all proteins of known domain composition.
2.1 Set of potential domains
The sets of potential domains (Pi) are inferred from the results of Pfam
HMM searches using hmmer software (Eddy, 1998). Given a set of proteins
and an HMM, this tool computes a score that measures the similarity
between each protein sequence and the domain modeled by the HMM.
Additionally, this score can be used to compute an E-value estimate that
represents the expected number of random sequences that would obtain a
score above that achieved by the protein. Here, the set of potential domains
of each protein is built by considering all HMM hits that differ from the
already known Pfam domains and which have an E-value below a given
permissive threshold (e.g. 10). This E-value threshold is chosen to be much
less conservative than the thresholds recommended by Pfam for each HMM.
The results are then processed for each protein to obtain a list of non-
overlapping potential domains. The policy applied for this selection is to
favor domains with the most significant (lowest) E-values. Overlaps with
already known Pfam domains are forbidden. The same domain may appear
several times in this non-overlapping domain list, but redundancies are
removed to obtain the final set of potential domains Pi.
2.2 Set of validating domains
Different sets of validating domains (Vi) are considered here. The first
solution is to use known Pfam domains of the protein. A complementary
solution is to use InterPro non-Pfam domains already known in the protein.
This allows us to increase the number of validating domains of each
protein and thus the expected number of certifications. However, due to the
heterogeneity of the InterPro database, the certifications achieved this way
may be of lower quality than that achieved with Pfam domains. With these
first two solutions, domains can be certified solely in proteins where at least
one domain is already known. To overcome this limitation, a third solution is
to consider the potential domains themselves as validating domains. In this
solution, all pairs of potential domains of the protein are enumerated and,
if the pair belongs to the CDP list, the two domains are certified. Of course
this procedure is more prone to false positives than the two others, but we
will see below how this can be controlled. Thus, the three types of validating
domains are mutually exclusive and of decreasing quality a priori. Note that
when certifying a potential domain, only the validating domains that do not
overlap this domain are considered. In the experiments below, the three types
of validating domains are used and tested independently.
2.3 Selecting the CDPs
The list of Conditionally Dependent Pairs is computed from the whole set
of domain pairs observed in Uniprot proteins of all organisms but the query
organism. Only pairs of different domains are considered in the CDP list,
in order to avoid certifying one domain by itself. These pairs must reveal a
conditional dependence between a Pfam domain and an InterPro (Pfam or
non-Pfam) domain, that is, the presence of the InterPro domain has to be
a strong clue of the presence of the Pfam domain. Testing the conditional
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dependence of a domain pair involves measuring the association between
two variables. This can be done with a correlation test like χ2. Here we
use a one-tailed Fisher’s exact test to cope with small sample sizes. To this
end, we compute, for each domain pair (A,B), A 6= B, the number x of
proteins where both A and B are present, the numbers w (respectively y)
of proteins where A is present but B is absent (resp. A is absent but B is
present), and the number z of proteins where both A and B are absent. The
probability of observing x or more proteins with the B domain in the set of
x+w proteins having the A domain, under the null hypothesis that domains




P (x+ t, y − t, w − t, z + t), (1)
withP (α, β, γ, δ) being the probability of observing exactly α proteins with
B among α + γ proteins, knowing that there are a total of α + β proteins
with B among a total number of α+β+γ+ δ proteins. Hence, a p-value is
computed with expression (1) for each domain pair. If this p-value is below
a given threshold—1% in our experiments—the null hypothesis is rejected,
the domains are considered as conditionally dependent, and the pair is added
to the CDP list.
2.4 Estimating the number of false certifications
From the potential domains, the validating domains, and the CDP list,
we can certify a certain number of new domains. One issue is then to
estimate the proportion of false positives among these new domains. To
this end, we estimate the probability of certifying a potential domain under
the null hypothesis H0 that it has been randomly predicted. This is done
through computer simulations, by shuffling the potential domains of all
proteins. This procedure randomly permutes the potential domains, while
avoiding associating the same domain to a given protein more than once.
This creates a situation where the potential domains are independent of
the validating domains, while preserving the domain distribution and the
number of validating and potential domains in each protein. The certification
procedure is applied to the shuffled domains, and the number of random
domains certified is computed. The entire procedure is resumed several times
(typically 1000 times) to get a reliable estimate of the expected number of
domains our procedure would certify under the hypothesis that all potential
domains are random. This number is then used to compute an estimate of the
False Discovery Rate (FDR) of the certification process with the formula
F̂DR =
expected number of certifications under H0
number of certifications on original data
. (2)
This approach is similar to that proposed in Soric¸ (1989) and Benjamini
and Hochberg (1995) to control the FDR associated with the multiple
testing of several hypotheses. We shall see that by modulating the E-value
threshold used to define the set of potential domains, we can control the
FDR associated with our certifications through this procedure.
3 RESULTS
3.1 Method assessment
We first assessed the potential of the method to improve the Pfam
sensitivity in divergent proteins. In this experiment, Saccharamyces
cerevisiae was chosen for the quality of its annotations. The
principle is as follows. Pfam HMMs were used with their score
thresholds to determine a set of reference domains in yeast. All
proteins with at least two Pfam domains were considered for the
following steps. We simulated the evolution of these proteins using
seqgen (Rambaut and Grassly, 1997) in order to change their global
amino-acid composition and make it close to that of P. falcipa-
rum. seqgen was used with the WAG substitution rate matrix, but
we replaced the default standard amino-acid composition by that
of P. falciparum (PlasmoDB 5.5). Starting from any sequence and
Table 1. Results on yeast after sequence drift
Subst. Lost Potent. Retr. FDR New Known
Rate Dom. Retr. Dom. Dom. GO
0.1 149 145 134 11.5% 274 97/130
0.25 346 301 265 9.2% 171 72/93
0.5 907 645 491 5.4% 60 20/31
0.75 1436 747 501 4% 12 7/12
“Subst. Rate”: substitution rate applied to the sequences; “Lost Dom.”:
number of domains that are not found with Pfam thresholds in the
drifted sequences; “Potent. Retr.”: number of domains which might be
retrieved (i.e. lost domains in proteins where at least one other domain
is still detected by Pfam thresholds); “Retr. Dom.”: number of lost
domains retrieved by our approach; “New Dom.”: number of certified
domains that do not belong to the reference domain set; “Known GO”:
proportion of annotated new domains with annotations already known in
the corresponding proteins.
applying substitutions based on this modified matrix, we obtained
a sequence with an amino-acid composition converging toward the
P. falciparum distribution. Four different substitution rates were
applied—0.1, 0.25, 0.5 and 0.75—yielding four sets of artificial
protein sequences of increasing divergence from the original yeast
proteins. For each of these sets, each HMM was used with the
Pfam score thresholds to determine the set of validating domains.
Some reference domains were no longer detected because of the
sequence drift. The certification procedure was then applied with
these validating domains to retrieve the lost domains.
Table 1 summarizes the results. For example, with a substitution
rate of 0.5, 907 domains are lost; among these, 645 might be
retrieved (i.e. belong to a protein where at least another domain
is still detected using the Pfam thresholds), and 491 (76%) are
actually retrieved. Moreover, 60 new domains (absent from the
original reference set) are also certified (with a small 5.4% FDR).
The number of new domains is even higher for lower substitution
rates, and may appear surprisingly high in a well annotated organism
like yeast. This questions the validity of these new domains.
Addressing this issue is not easy. One solution is to refer to the GO
annotations associated with domains. Indeed, when GO annotations
associated with a newly discovered domain are already known in the
corresponding protein, the domain is likely to be present. The last
column of Table 1 reports the proportion of new domains with GO
annotations that are in agreement with those of the corresponding
proteins. For example, for the 0.1 substitution rate, 130 of the 274
new discovered domains are annotated, among which 97 (75%) have
annotations already known in the associated proteins. This high
proportion suggests that a large part of the new domains are not
false positives, but rather true domains recovered by our approach.
3.2 Reannotation of P. falciparum proteins
The method was applied to P. falciparum using the three different
types of validating domains discussed in the Method section: 1)
known Pfam domains; 2) known InterPro domains (excluding Pfam
domains); and 3) potential domains themselves. Known Pfam and
InterPro domains were obtained using the InterProScan software
(release 19.0) that was applied to the P. falciparum proteome
(PlasmoDB release 5.5). For potential Pfam domains, different
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Fig. 1. Evolution of the number of certifications and FDR as a function
of the E-value. Number of certifications (thick line), expected number of
certifications under H0 (thin line), and FDR (dashed line) achieved when
modulating the E-value thresholds (x-axis). The number of certifications and
errors (thin and thick lines) are read on the left y-axis, while the FDR
(dashed line) is read on the right one.
E-value thresholds were used in order to obtain predictions with
various FDRs.
Figure 1 reports the number of certified domains and FDR
achieved with known Pfam domains when varying the E-value
threshold used to select the potential domains. Both the number of
certified domains and the FDR increase with the E-value threshold,
which illustrates the potential of the method to control the FDR by
simply modulating this threshold.
Table 2 summarizes the results achieved for FDRs below 10%
and 20% with the three types of validating domains. For example,
for FDR ≤ 20%, 585 new domains are certified. This is an
increase of ∼ 16% compared to the 3 683 already known Pfam
domains in P. falciparum proteins (only one occurrence of each
known/new domain per protein is considered here; Pfam release
23.0). Among these, 479 involve a new InterPro domain family in
the protein. The known Pfam domains allow certification of 363
of the 585 new domains, the known InterPro domains 395, and the
potential domains themselves 130 (several new domains are certified
by 2 or 3 of the validating domain types). Moreover, 159 new
domain types are discovered—i.e. which had never been previously
detected in P. falciparum proteins—, an increase of 11% of the
total number of domain types known in P. falciparum (see Supp.
Table 1). The Supp. Figure 1 shows the number of certifications as
a function of the FDR achieved by each type of validating domain.
For a given FDR, the potential domains allow the certification of
fewer domains than the two other types. This is not a surprise, as
these validating domains are potentially false. Hence, very low E-
value thresholds are required to achieve low FDRs, which induces
the selection of small amounts of potential-validating domains.
We then addressed the difficult issue concerning conservation
of the functionality of the new domains. We tried to answer this
question by looking at two different indicators. First, as explained
in the Introduction, P. falciparum proteins often involve long low
complexity regions, and these regions are suspected to primarily
affect the non-functional parts of sequences. However, a comparison
of the proportions of low complexity regions in newly certified
domains and in already known domains does not reveal significant
differences (see Supp. Table 2). We next investigated the positions
where the new domains are discovered. Indeed, Weiner et al. (2006)
showed that domain divergence events (especially domain loss due
Table 2. Results on P. falciparum
FDR ≤ 10% ≤ 20%
Valid. dom. Pfam Interp. Pot. All Pfam Interp. Pot. All
Certif. Dom. 259 185 47 340 363 395 130 585
New Interp. 200 138 39 259 298 318 114 479
New Dom. Types 70 51 13 90 106 105 36 159
“Valid. dom.” indicates the type of validating domains used for certifications: “Pfam”,
known Pfam domains from InterProScan; “Interp.”, known InterPro (non-Pfam)
domains from InterProScan; “Pot.”, potential domains themselves. “All”: results
achieved when combining the 3 types; “Certif. dom.”: number of new certified
domains; “New Interp.”: number of certification allowing us to identify a new InterPro
Entry for the protein; “New Dom. Types”: number of domain types that were not
previously detected in any P. falciparum proteins.
to loss of functionality) occur primarily at the ends of the proteins.
Here again, when comparing the distances separating known and
new domains from protein ends (see Supp. Figure 2), no bias
towards the ends can be observed in the new domains. Hence, no
bias is found in these two indicators, which seems to indicate that
the proportion of new domains that are non-functional is not higher
than that of the already known domains.
We next investigated GO annotations that could be deduced from
these newly identified domains. As described in the Introduction,
some domains have been associated with specific GO terms by
the InterPro consortium. The policy is to associate, with a given
domain, annotations shared by all annotated proteins possessing
this domain. Moreover, by extending this policy to domain
combinations—as described in Forslund and Sonnhammer (2008)—
, several additional GO terms can be deduced from the combination
of two or more domains. To this end, we enumerated all Pfam
domain combinations in the proteins of Swiss-Prot, and identified
for each combination the GO terms shared by all annotated proteins
where the combination is present (only combinations observed in
at least 10 annotated proteins were considered). We found 2 235
Pfam domain combinations associated with at least one specific
GO annotation: 2 115 domain pairs, 119 domain triplets and 1
quartet. All associations between domain combinations and GO
terms are available in the Supplementary Material1. Altogether,
single domains and domain combinations improve the annotations
of several P. falciparum proteins. Table 3 summarizes the results.
For example, with a FDR ≤ 20%, the newly certified domains
leads to the discovery of 273+114 = 387 new GO annotations, i.e.
6% of the 5 791 already known GO annotations of this organism (in
the three ontologies).
All results with FDR ≤ 40% are available in an online database
at URL http://www.lirmm.fr/∼terrapon/codd/. The newly predicted
Pfam domains of P. falciparum proteins are displayed along with
their associated FDR and the Pfam/InterPro validating domains
used for certification. Figure 2 presents an extract from the database
for the PF11 0189 gene.
When browsing this database, several points can be noted.
First, annotations of already annotated genes can be enriched
1 http://www.lirmm.fr/∼terrapon/codd/
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Fig. 2. Known and newly predicted domains of gene PF11 0189. Four domains are already known: three InterPro (Gene3D, Panther and Superfamily)
domains (G3DSA:3.30.830.10, PTHR11851:SF68, and SSF63411) and one Pfam domain (PF00675). We see the localizations of these domains and
the associated GO terms. Moreover, two new Pfam domains have been discovered: PF08367 and PF05193. For example, PF05193 has been discovered
in two positions: the first one with an E-value of 0.042 and the second one with an E-value of 0.044. These E-values are too high to be safely considered
according to the recommended Pfam threshold for this domain. However, they have been certified by several validating domains. For example, the domain
in second position is certified by the known Pfam domain PF00675 with a FDR = 4.71% , the known InterPro domains G3DSA:3.30.830.10 and
SSF63411 (FDR = 9.66%), and the potential (and also newly certified) Pfam domain PF05193 (FDR = 19.5%). Note that the domain in first position
is not certified by the two InterPro domains because it overlaps these domains. PF05193 is associated with two GO annotations already known for the gene
(proteolysis and metalloendopeptidase activity) and one new annotation (zinc ion binding). Moreover, since it is found together
with domains PF08367 and PF00675, it is also associated with GO terms mitochondrion and cell part
.
in numerous cases. For example, MAL7P1.12, annotated as an
“erythrocyte membrane-associated antigen”, is ascribed a novel
possible molecular activity related to RNA control, based on
detection of PF00035 and PF04851. Next, a function is predicted
for several genes listed as hypothetical in PlasmoDB 5.5. For
example, MAL13P1.78 is possibly a protein kinase (based on
the detection of the PF06743 domain), PF10 0040 a nuclease
involved in DNA repair (based on PF00867 and PF00752
domains), PF10 0152 a nucleotidyltransferase (PF01909 and
PF03828 domains), PF11 0244 an ATP-dependent protease
(PF02190 domain), etc. In this list of new putative annotations,
novel potential targets for antimalarial therapeutics might be
envisaged, including, for example, the PF14 0052 protein
for which certification of the PF07683 domain (confirming
PF02492) indicates that it might be involved in the synthesis
of cobalamin (vitamin B12), a molecule necessary for the
parasite’s development. Similarly, the putative tetrahydrofolate
dehydrogenase/cyclohydrolase PFF1490w (confirmation of PF-
02882 by PF00763), is a new enzyme of the folate metabolism,
which should now be experimentally investigated. Detection of the
PF05605 domain in PF14 0479 is also very interesting, since
it is extremely specific to the plant kingdom, associated with the
5
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Table 3. New GO annotations of P. falciparum proteins
FDR Single Combin. Combin. with Total Unannot.
Domains Known Dom. Certified Dom. Prot. prot.
≤ 10% 128 122 74 194 20
≤ 20% 273 122 114 267 39
“Single Domains” is the number of new GO annotations brought by a single domain
certified by our approach; “Combin. Known Dom.” is the number of GO annotations
that can be deduced from combinations of already known domains thanks to inferred
associations between domain combinations and GO annotations; “Combin. with
Certified Dom.” is the number of supplementary GO annotations (different from the
2 previous columns) that can be deduced from combinations involving a newly certified
domain. “Total Prot.” is the total number of proteins involved, and “Unannot. Prot.” is
the number of proteins without any annotation and for which an annotation has been
proposed.
response of plants to drought, and likely acquired in P. falciparum
following ancestral endosymbiosis with an alga at the origin of the
plant-like features in Apicomplexa (Kohler et al., 1997).
Overall, we observe that families of proteins containing domains
related to RNA binding, modification and/or processing (Helicase
C, RRM, DEAD) are amongst the largest in the P. falciparum
genome. It also appears that domains involved in protein-protein
interactions, e.g. WD40, together with TPR 1 (initially identified in
16 sequences, now in 28 proteins) or TPR 2 (initially identified in
12 sequences, now in 27 proteins), are also detected in large protein
families. Moreover, the newly certified domains reveal proteins
involved in chromatin interaction (such PFF1385w, PFL0975w or
PF07 0106) and numerous transcription factor associated proteins,
which are of particular interest for future investigation considering
the apparent lack of such proteins in initial studies (Coulson et al.,
2004; Callebaut et al., 2005). The present work therefore allows an
in-depth analysis of these families, with greater genomic coverage.
An extended biological appraisal of these results, with several
additional examples, is available in the Supplementary Material.
3.3 Application to other Plasmodium species
Finally, we applied the procedure to the proteomes of P. vivax and P.
yoelii, two other sequenced Plasmodium species infecting humans
and rodents, respectively. The results can be browsed at the same
URL2. Statistics on the number of newly certified domains and GO
annotations are in Supp. Tables 3 and 4 and in Supp. Figure 3. The
number of newly certified domains is slightly higher in P. falcipa-
rum than in the other species. Importantly, a large part of the newly
certified domains in P. falciparum proteins are also certified in P.
vivax and P. yoelii, while another part corresponds to already known
domains in these organisms (see Supp. Tables 5 and 6). For example,
among the newly certified domains (FDR ≤ 10%) in the P. falcipa-
rum proteins with a known homologue in P. vivax, 14% are already
known in the P. vivax homologue and 69% are also certified in this
homologue. Thus, 83% of the new domains are also found in P.
vivax homologues. These results strongly support our method and
our findings in the P. falciparum proteome, and can be seen as a
third indicator that our new domains are still functional.
2 http://www.lirmm.fr/∼terrapon/codd/
4 DISCUSSION AND CONCLUSION
Enhancing domain detection is a complex task. Practically, domain
models are designed to ensure the presence of a domain thanks to
manually curated score thresholds. Beyond the thresholds, avoiding
false positives is no longer guaranteed. In this paper, we propose
a method to filter out false positives from hits with scores in the
twilight zone below the thresholds. To the best of our knowledge,
two previous works address related issues. Beaussart et al. (2007)
designed a tool that helps identify possible annotation artifacts,
notably missing domains. This is achieved by searching for clusters
of proteins with similar domains, and aligning the proteins of each
cluster on the basis of their domain arrangement. Then a missing
domain can be detected in a protein by looking at the domain
composition of all proteins in the same cluster which have high
similarity with the query sequence. This can be an efficient strategy
if a protein homologous to the query protein is already known
and correctly annotated. Coin et al. (2003) propose an elegant
approach to increase the sensitivity of HMM domain detection
by incorporating context information. Rather than independently
detecting each domain of a protein sequence, the authors propose
a Markov model that allows global detection of the domain
composition of the protein. With this model, the score achieved
by a domain at a given position is a function of both the protein
sequence and the other potential domains of the protein. A precise
comparison of the results achieved with this approach is difficult,
as the databases they used have been enriched. However, we can
get a rough comparison by concentrating on P. falciparum proteins
present in the Swiss-Prot40 data the authors analyzed. Swiss-Prot40
involved 491 P. falciparum proteins. In these proteins, our method
allows the certification of 36 new domains with a FDR ≤ 20%,
while Coin et al. (2003) propose 5 new domains. Among these 5
domains, 1 is also certified by our method. Among the 4 remaining
domains, a close inspection of the protein compositions reveals that
2 proteins contain repeats of a single domain. In other words, for 2
cases, the domain has been used to improve its own detection, which
is a certification mechanism we did not consider here.
Compared with previous works, our approach has several
appealing features. First, it is a simple and intuitive approach
which has low computing time and can potentially be used on any
genome. Second, each prediction can be explained by exhibiting
the validating domain(s) that enables discovery of the new domain.
Third, we can benefit from all types of domain information
already known in the InterPro database, as well as in any other
domain database. Finally, and most importantly, an estimate of the
confidence of the certifications can be computed with our shuffling
procedure.
The approach proved to be promising with P. falciparum. With
FDR ≤ 20%, it allows us to increase the total number of
known domains by 16%, the number of different known domain
types by 11%, and the number of known GO annotations by 6%.
Analogous and congruent results are obtained on P. vivax and P.
yoelii. Moreover, experiments on yeast showed that the method
could also benefit better annotated organisms. Since domain co-
occurrence is the strongest source of information, this work did
not consider the adjacency and sequential order of the domains.
However, as these features are also often conserved (Kummerfeld
et al., 2009), it is likely that taking some ordering information into
account would improve the approach.
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